Haematological malignancies (e.g. leukaemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, myeloproliferative disorders)
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: <Recipient>. 1 Persons aged 18 years or older at the time consent is obtained. 2 Performance Status (PS) 0-2 (Ref. 1) 3 After receiving a full explanation of their participation in the study, and with full understanding, the research subject's own 1 Persons who have given their free and voluntary consent <donor 1 Persons who are at least 18 years of age at the time consent is obtained. 2 Persons who perform peripheral blood stem cell collection in daily medical practice 3 Persons who are considered to require daily G-CSF or pegfilgrastim administration for peripheral blood stem cell collection 3 Persons for whom daily G-CSF or pegfilgrastim administration is considered necessary for peripheral blood stem cell collection 4 Persons who, after receiving a full explanation and with full understanding, have given their free and voluntary consent to participate in this study. 4 Persons who, after full explanation of their participation in the study, have given their free and voluntary consent based on a thorough understanding of the situation.
Exclusion criteria
Exclusion criteria: <Recipient>. 1 Persons who are considered to be at high risk of failure to thrive (as judged by the attending physician). 2 Other persons deemed unsuitable as research subjects by the principal investigator. <Donor 1 Persons who are deemed ineligible during the preoperative medical examination. 2 Other persons deemed unsuitable as research subjects by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of engraftment rates after allogeneic transplantation between G-CSF and pegfilgrastim. | — |
Secondary
| Measure | Time frame |
|---|---|
| <Recipient>. 1 Adverse events after stem cell infusion 2 Failure of engraftment 3 Time from infusion to blood cell engraftment 4 Rate and duration of blood cell engraftment by disease 5 Blood cell engraftment rate and duration by pre-transplant treatment 6 Blood cell engraftment rate and duration by number of stem cells infused 7 Blood cell engraftment rate and duration by GVHD prophylaxis <Donor 1 CD34-positive cells mobilised into peripheral blood after G-CSF administration 2 Adverse events after G-CSF administration 3 Number of harvested stem cells by G-CSF 4 Fractionation of harvested stem cells by G-CSF 5 Differences in the number of stem cells collected on different collection days (e.g. day4 or day5) 6 Differences in collection efficiency due to differences in collection equipment and settings 7 Relationship between changes in blood levels of cytokines and adverse events | — |
Countries
Japan
Contacts
Public ContactHideki Goto
Hokkaido University Hospital Division of laboratory and transfusion medicine
Outcome results
None listed